): The University of Colorado Cancer Center is requesting continuing support for their participation in the Southwest Oncology Group (SWOG). The mission of the University of Colorado Cancer Center has, since it's founding, been the reduction of cancer mortality through basic laboratory research, moving scientific discoveries to the clinic through translational research, and the design, execution, and analysis of clinical trials. Their participation in SWOG has been an integral part of the mission of the University of Colorado Cancer Center. Institutional pilot studies conducted at the University of Colorado have been brought to the Group in the form of prospective randomized trials. SWOG members from the University of Colorado have and continue to contribute to the administrative, educational and scientific functions of SWOG. University of Colorado SWOG members are chairs or co-chairs of the following committees: Genitourinary (Dr. E. David Crawford), Blood and Marrow Transplantation (Dr. Elizabeth Shpall), GU Pathology (Dr. Gary Miller), and Lung Biology (Wilbur Franklin). Dr. Scott Bearman is Principal Investigator for SWOG and sits on the Board of Governors. In addition to these administrative contributions, University of Colorado Cancer Center members are coordinators or co-coordinators of 17 percent of the SWOG protocols activated during the previous grant period. Presently, University of Colorado members are important contributors to the Blood and Marrow Transplantation, Breast, Lung, and GU Committees. During the next five years they expect to continue to make important scientific and administrative contributions to those committees. In addition, they expect to contribute in other areas as well, including radiotherapy (Drs. Rachel Rabinovitch and Michael Weil), developmental therapeutics (Dr. Andrew Kraft), neuro-oncology (Dr. Bertrand Liang) and Cancer Control (Dr. Marie Wood). They are proud of our contributions to the Southwest Oncology Group and are committed to its mission. They expect their contributions to increase during the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA042777-12
Application #
2856267
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1998-01-21
Project End
2002-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
NSCLC Meta-analysis Collaborative Group (2014) Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383:1561-71
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9

Showing the most recent 10 out of 222 publications